Compare Grab Holdings Ltd. (GRAB) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Humana Inc — how do they compare? Grab Holdings Ltd. trades at $3.2 (market cap $12.72B), while Humana Inc trades at $433 (market cap $46.49B). The key difference: Humana Inc is far larger — about 3.7× Grab Holdings Ltd.'s market cap, and Humana Inc pays a 0.91% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Humana Inc for 51 Days on average.
| GRAB | HUM | |
|---|---|---|
Market Cap | $12.72B | $46.49B |
Volume | 65,352,859 | 2,567,704 |
Sector | Technology | Health |
52-Week High | $6.17 | $409.85 |
52-Week Low | $2.80 | $163.67 |
Typical Hold Time | 94 Days | 51 Days |
Enterprise Value | $8.46B | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.19, up 3.57% today, with a bearish technical signal but strong fundamental momentum. The company has delivered three consecutive quarterly EPS beats, with Q2 2026 revenue up 22% year-over-year to $997 million. Recent news highlights a $1.49 billion acquisition of a majority stake in Atome Financial and a $30 million CEO share purchase, signaling confidence in growth. Cash flow trends show volatility, with 2025 net cash flow positive at $469 million but a projected decline to -$1.0 billion in 2026.
The outlook for GRAB is supported by robust revenue growth, expanding profitability, and aggressive financial services expansion, but risks include high capital expenditure, competitive pressures in Southeast Asia, and potential regulatory scrutiny. Analyst consensus is strongly bullish with 91.67% buy ratings, though technical indicators suggest near-term caution. The stock's valuation at a P/E of 28.27 reflects growth expectations but requires sustained execution to justify.
Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.
The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
